Q3 Earnings Forecast for PHIO Issued By Sidoti Csr

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Equities researchers at Sidoti Csr issued their Q3 2025 earnings per share (EPS) estimates for Phio Pharmaceuticals in a note issued to investors on Wednesday, October 29th. Sidoti Csr analyst A. Hantman anticipates that the company will earn ($0.44) per share for the quarter. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. Sidoti Csr also issued estimates for Phio Pharmaceuticals’ Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.77) EPS, Q1 2026 earnings at ($0.29) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.26) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.09).

A number of other analysts also recently issued reports on PHIO. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Phio Pharmaceuticals in a report on Friday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $14.00.

Phio Pharmaceuticals Stock Performance

NASDAQ PHIO opened at $1.63 on Monday. Phio Pharmaceuticals has a 52-week low of $0.97 and a 52-week high of $9.79. The company has a 50-day simple moving average of $2.17 and a 200 day simple moving average of $2.20. The company has a market capitalization of $9.34 million, a PE ratio of -0.50 and a beta of 0.95.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Geode Capital Management LLC increased its holdings in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 57,694 shares of the company’s stock after buying an additional 16,108 shares during the quarter. Geode Capital Management LLC owned 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent reporting period. 57.31% of the stock is owned by institutional investors and hedge funds.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.